X4 Pharmaceuticals lands $27 mln Series B
Cambridge, Massachusetts-based X4 Pharmaceuticals, a developer of novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, has closed $27 million in Series B financing. The investors were not named.
16 November 2017•1 min read
